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A BS T R AC T
BACKGROUND

The prevalence and spectrum of predisposing mutations among children and adolescents with cancer are largely unknown. Knowledge of such mutations may improve the
understanding of tumorigenesis, direct patient care, and enable genetic counseling of
patients and families.
METHODS

In 1120 patients younger than 20 years of age, we sequenced the whole genomes (in
595 patients), whole exomes (in 456), or both (in 69). We analyzed the DNA sequences
of 565 genes, including 60 that have been associated with autosomal dominant cancerpredisposition syndromes, for the presence of germline mutations. The pathogenicity
of the mutations was determined by a panel of medical experts with the use of cancerspecific and locus-specific genetic databases, the medical literature, computational
predictions, and second hits identified in the tumor genome. The same approach was
used to analyze data from 966 persons who did not have known cancer in the 1000
Genomes Project, and a similar approach was used to analyze data from an autism
study (from 515 persons with autism and 208 persons without autism).
RESULTS

Mutations that were deemed to be pathogenic or probably pathogenic were identified in 95
patients with cancer (8.5%), as compared with 1.1% of the persons in the 1000 Genomes
Project and 0.6% of the participants in the autism study. The most commonly mutated genes
in the affected patients were TP53 (in 50 patients), APC (in 6), BRCA2 (in 6), NF1 (in 4), PMS2
(in 4), RB1 (in 3), and RUNX1 (in 3). A total of 18 additional patients had protein-truncating
mutations in tumor-suppressor genes. Of the 58 patients with a predisposing mutation
and available information on family history, 23 (40%) had a family history of cancer.
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CONCLUSIONS

Germline mutations in cancer-predisposing genes were identified in 8.5% of the children and adolescents with cancer. Family history did not predict the presence of an
underlying predisposition syndrome in most patients. (Funded by the American Lebanese Syrian Associated Charities and the National Cancer Institute.)
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he frequency of germline mutations in cancer-predisposition genes in
children and adolescents with cancer and
the implications of such mutations are largely
unknown. Previous studies have relied mainly
on candidate-gene approaches, which are, by design, limited. To better determine the contribution of germline predisposition mutations to
childhood cancer, we used next-generation se-
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quencing, including whole-genome and wholeexome sequencing, to analyze the genomes of
1120 children and adolescents with cancer. We
describe the prevalence and spectrum of germline variants among 565 cancer-associated genes,
with an emphasis on the analysis of 60 genes
that have been associated with autosomal dominant cancer-predisposition syndromes. We also
reviewed records of patients with mutations and
those without mutations in these 60 genes for
information on family history of cancer.

A SEER Program

Me thods
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Figure 1. Frequency of Pediatric Cancer Types among Patients Younger
than 20 Years of Age.
Panel A shows the distribution of pediatric cancer types on the basis of
data from the Surveillance, Epidemiology, and End Results (SEER) program.
Panel B shows the distribution of cancer types analyzed by the Pediatric
Cancer Genome Project (PCGP). ACT denotes adrenocortical tumor, CNS
central nervous system, and STS soft-tissue sarcoma.
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The 1120 patients included in this study represented the major subtypes of pediatric cancer
(Fig. 1; and Table S1 in Supplementary Appendix 1,
available with the full text of this article at
NEJM.org). Whole-genome, whole-exome, or both
types of sequencing data were generated with
the use of germline DNA for 595, 456, and 69
patients, respectively, as part of the St. Jude–
Washington University Pediatric Cancer Genome
Project (PCGP; www.ebi.ac.uk/ega/search/site/
PCGP). To verify predictions of aberrant splicing
caused by variants affecting splice junctions, we
sequenced the RNA transcripts extracted from
522 samples of tumor tissue obtained from 522
patients. The study was approved by the institutional review board at St. Jude Children’s Research Hospital. Written informed consent was
provided by a parent or guardian of each child
or by a patient who was 18 years of age or older.
Whole-exome sequencing data from two control cohorts of persons without known cancer
were analyzed. The first data set, a raw wholeexome sequencing data set from 966 unrelated
adults who were part of the 1000 Genomes
Project (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/
phase3), was analyzed by the same approach

that was used in our pediatric cancer cohort.
The second data set consisted of genotype files
of 515 persons with autism and 208 persons without autism (median age, 6 years; range, 1 to 37)
from the National Database for Autism Research
(https://ndar.nih.gov/study.html?id=307). Analyses
of this second data set did not involve variant
detection owing to a lack of access to raw sequence data, and we excluded two cancer-predisposition genes, NF1 and PTEN, which are known
to be associated with an autism spectrum phenotype (Supplementary Appendix 1).
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Figure 2. Categories of the 565 Cancer Genes Analyzed for Germline Mutations.
The number of genes in each category is shown in parentheses. Genes that have overlapping categories are listed
only once. Gene names in the other categories are shown in Figure S9 in Supplementary Appendix 1. RASopathies
are genetic syndromes that include the cardiofaciocutaneous syndrome, Costello’s syndrome (also called the faciocutaneoskeletal syndrome), Noonan’s syndrome, and the multiple lentigines syndrome.

Cancer-Predisposition Genes Selected
for Analysis

A total of 565 genes were chosen for analysis on
the basis of review of the American College of
Medical Genetics and Genomics (ACMG) gene
list and the medical literature1-4 and were divided
into five nonoverlapping categories (Fig. 2; and
Table S3 in Supplementary Appendix 1 and Table
S2 in Supplementary Appendix 2, available at
NEJM.org). The first category included genes that
have been associated with autosomal dominant
cancer-predisposition syndromes, and it consisted
of 49 classical genes (including 23 genes from the
ACMG gene list5) and 11 genes that have been
implicated in genetic syndromes associated with
RAS mutations (sometimes called RASopathies;
these include the cardiofaciocutaneous syndrome,
Costello’s syndrome [also called the faciocutaneoskeletal syndrome], Noonan’s syndrome, and the
multiple lentigines syndrome). These 60 genes
were selected because of the potential effect of
germline mutations on clinical practice, including
avoidance of radiation therapy, choice of surgical
approach for tumor resection, donor testing and
selection for hematopoietic stem-cell transplantation, possible or proven benefits of tumor surveillance and early cancer detection, and risk-reductive surgery.3 Variants detected in these 60 genes
were confirmed experimentally by an independent
sequencing assay (Supplementary Appendix 1).
The second category included 29 genes that
have been associated with autosomal recessive
cancer-predisposition syndromes, with a focus
on identifying biallelic pathogenic mutations.

Variants detected in the 89 genes that have been
associated with autosomal dominant or autosomal
recessive cancer-predisposition syndromes were
reviewed by a multidisciplinary panel for classification and reporting.5-8
An additional 476 genes were chosen for
evaluation on the basis of their recurrent somatic mutation in cancer (http://cancer.sanger
.ac.uk/cancergenome/projects/census and www
.pediatriccancergenomeproject.org/site). These
genes were classified into three categories: tumorsuppressor genes (58 genes),9 tyrosine kinase
genes (23), and other cancer genes (395). Our
analyses of the genes in these three categories
focused on known hotspot-activating mutations
in genes encoding kinases and on truncation
mutations in genes encoding tumor-suppressor
proteins and in other cancer genes.
Data Analysis

The sequencing data were analyzed for the presence of single-nucleotide variants and small insertions and deletions10 and for evidence of germline mosaicism (Supplementary Appendix 1).
Germline copy-number variations and structural
variations were identified with the use of the
Copy Number Segmentation by Regression Tree
in Next Generation Sequencing (CONSERTING)11
and Clipping Reveals Structure (CREST)12 algorithms. Common germline structural variations
and structural variations that did not affect coding exons were excluded from the analysis.
Nonsilent coding variants that passed qualitycontrol and minor-allele population frequency
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checks were classified as pathogenic, probably
pathogenic, of uncertain significance, probably
benign, or benign. Classification criteria included
information from curated databases, computational predictions of mutational effect on protein function, and recent ACMG guidelines for
interpretation.13 Full details of the data analysis
and interpretation are provided in Figure S1 in
Supplementary Appendix 1.

R e sult s
Characteristics of the Patients

The PCGP cohort included 588 children and adolescents with leukemia (52.5%), 245 with central
nervous system (CNS) tumors (21.9%), and 287
with non-CNS solid tumors (25.6%) (Fig. 1, and
Table S1 in Supplementary Appendix 1). The
median age of the patients was 6.9 years (range,
8 days to 19.7 years). The cancers that were selected for sequencing included those that have
been associated with a poor clinical outcome
(e.g., hypodiploid leukemia)14 and those without
a clearly defined oncogenic cause (e.g., diffuse
intrinsic pontine glioma).15 Our cohort included
more patients with leukemia and adrenocortical
tumors than was expected on the basis of the
population in the Surveillance, Epidemiology, and
End Results (SEER) program (http://seer.cancer
.gov/iccc) (Fig. 1). Lymphoma, Wilms’ tumor,
germ-cell tumors, non-rhabdomyosarcoma softtissue sarcoma, and hepatoblastoma were not
included because of an inadequate number of
samples for high-risk subtypes.
Germline Mutations in Cancer-Predisposition
Genes

In the 60 genes that have been associated with
autosomal dominant cancer-predisposition syndromes, we identified 633 nonsilent germline
variants, of which 78 (12%) were deemed to be
pathogenic, 17 (3%) probably pathogenic, 226
(36%) of uncertain significance, 273 (43%) probably benign, and 39 (6%) benign (Table S4A in
Supplementary Appendix 2). The 95 variants that
were deemed to be pathogenic or probably pathogenic included 54 missense mutations, 14 nonsense mutations, 12 frameshift mutations, 9 splicesite mutations, and 1 in-frame deletion, as well
as 5 copy-number alterations (Fig. S2 in Supplementary Appendix 1).
The 95 variants that were deemed to be pathogenic or probably pathogenic were detected in 21
4
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Figure 3 (facing page). Distribution of Germline Mutations
in Different Gene Categories and Cancer Subtypes.
Panels A and B include only mutations that were deemed
to be pathogenic or probably pathogenic and that affect
genes that have been associated with autosomal dominant cancer-predisposition syndromes, according to
tumor subtype. Panel A shows the distribution of mutations in each gene among patients with various cancers included in the PCGP cohort. Panel B shows the
prevalence of the mutations in each cancer subtype.
Five patients with melanoma without mutations are
not shown, and one patient (HGG027) who had a CNS
tumor with biallelic mutation in an autosomal recessive
gene (ATM) is not included in the summary. Panel C
shows the number of patients who had germline mutations considered to be pathogenic or probably pathogenic in genes that have been associated with autosomal
dominant (60 genes) and autosomal recessive (29) cancer susceptibility, according to cancer subtype. Panel D
shows the total number of patients who had truncation
mutations in tumor-suppressor genes, tyrosine kinase
genes, and other cancer genes, according to cancer
subtype.

of the 60 genes in 94 patients (Fig. 3A, and Fig.
S3 in Supplementary Appendix 1). TP53 was most
commonly involved (in 50 patients), followed by
APC (in 6), BRCA2 (in 6), NF1 (in 4), PMS2 (in 4),
RB1 (in 3), and RUNX1 (in 3). One patient (Patient HGG111) with café au lait spots and a highgrade glioma had 2 distinct PMS2 truncation
mutations, which indicated a diagnosis of biallelic mismatch-repair deficiency that was corroborated by the somatic hypermutation observed
in the genome of the high-grade glioma.15 The
most common cancer types that were associated
with germline TP53 mutations included adrenocortical tumors (in 27 of 39 patients [69%]),
hypodiploid acute lymphoblastic leukemia (in 9 of
47 [19%]), and choroid plexus carcinoma (in 1 of
4 [25%]) — findings that were consistent with
those in previous reports.14 As anticipated, the
tumors from all 37 of these patients had a loss
of heterozygosity at the TP53 locus (Table S4 in
Supplementary Appendix 2), including 1 patient
who had a germline deletion of 8.7 kb that removed TP53 exons 2 through 5 (Fig. S2 in Supplementary Appendix 1).
Four germline mutations were mosaic, with
the detected level of the mutant allele less than a
single copy (mutant allele fraction, 0.08 to 0.30).
One patient with retinoblastoma had a mosaic
RB1 mutation, and three patients with hypodiploid acute lymphoblastic leukemia had a mosaic
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sequencing at more than 2000× coverage verified
the mutant allele fraction within the germline and
tumor samples in each patient (Fig. 4).
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Figure 4. Distinguishing Mosaicism from Tumor Contamination.
Panel A shows that in the tumor-contaminated germline sample of Patient 1 (E2A019), most somatic mutations
were observed at a lower frequency in the germline than in the tumor. Nine genes were selected to show this point.
Panel B shows that in the case of mosaicism in Patient 2 (HYPO055), only one TP53 mutation was observed at a
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(arrows) were seen in the Sanger-sequencing chromatograph.
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In the first control data set, from the 1000
Genomes Project, we identified 11 pathogenic or
probably pathogenic mutations in the 60 genes
that have been associated with autosomal dominant cancer-predisposition syndromes; mutations were found in APC (in one person), BRCA1
(in one), BRCA2 (in four), MSH6 (in one), SDHA
(in one), SDHB (in one), and TP53 (in two) (Table
S6 in Supplementary Appendix 1). The prevalence of mutations was 1.1%, which was significantly lower than the 8.4% prevalence observed in the PCGP cohort (P = 5.9 × 10−16 by
Fisher’s exact test). A similar trend was observed in the second control set, which involved
participants from the autism study (frequency,
0.6%; P = 7.4 × 10−16 for the comparison with the
PCGP cohort) (Table S7 in Supplementary Appendix 1).
The PCGP cohort included a greater-thanexpected proportion of patients with hypodiploid acute lymphoblastic leukemia and those
with adrenocortical tumors (Fig. 1). However,
after these two subtypes were excluded, the
prevalence of germline mutations of 5.6% was
still significantly higher than the prevalence in
the two control cohorts (P<10−7 by Fisher’s exact test for both comparisons).
In our analysis of 29 autosomal recessive
cancer-predisposition genes, we observed only
one instance of biallelic pathogenic mutations
in 1 patient (Table S8 in Supplementary Ap
pendix 1). Combining data from this single
patient, who had ataxia telangiectasia caused
by biallelic mutations in ATM (Fig. S4 in Supplementary Appendix 1), with data from the
94 patients who had pathogenic mutations in
the 60 autosomal dominant cancer-predispo
sition genes, we observed an 8.5% prevalence
(95 of 1120 patients) of germline mutations
that were pathogenic or probably pathogenic
in the sample we analyzed. A total of 61 of the
93 patients (66%) with monoallelic germline
mutations had a second hit within the tumor
genome (Table S4 in Supplementary Appendix
2), as shown by loss of heterozygosity (in 57
patients) or mutational inactivation of the second allele (in 4). These data are available on
our pediatric cancer data portal (http://pecan
.stjude.org) (Figs. S5 and S6 in Supplementary
Appendix 1).

Prevalence of Germline Mutations across
Tumor Types

The prevalence of germline mutations that were
pathogenic or probably pathogenic was greatest
among patients with non-CNS solid tumors (48
of 287 patients [16.7%]), followed by those with
CNS tumors (21 of 245 [8.6%], including the
patient with biallelic loss of ATM) or leukemia
(26 of 588 [4.4%]) (Fig. 3B). The prevalence of
germline mutations varied among patients with
different subtypes of non-CNS solid tumors,
such as adrenocortical tumor (69.2%), osteosarcoma (17.9%), retinoblastoma (13.3%), Ewing’s
sarcoma (10.9%), rhabdomyosarcoma (7.0%),
and neuroblastoma (4.0%) (Fig. 3B). The histologic subtypes of CNS tumor that were most
often associated with germline mutations included choroid plexus carcinoma (in 1 of 4 patients [25%]), medulloblastoma (in 5 of 37
[13.5%]), high-grade glioma (in 9 of 99 [9.1%]),
low-grade glioma (in 3 of 38 [7.9%]), and ependymoma (in 4 of 67 [6.0%]). Overall, patients
with leukemia had the lowest prevalence of
germline mutations (4.4%), despite the inclusion
of patients with hypodiploid acute lymphoblastic
leukemia, a subtype with a high frequency of
germline mutation.14
Correlation between Germline Genotype
and Tumor Phenotype

The correlation of patient genotype with tumor
phenotype revealed several known associations
as well as some new ones. The known associations included the association of TP53 mutations
with classic Li–Fraumeni syndrome–associated
component cancers such as rhabdomyosarcomas,
osteosarcomas, adrenocortical tumors, CNS tumors, and leukemia; NF1 mutations with CNS
tumors; RB1 mutations with retinoblastoma and
osteosarcoma; and ALK mutations with neuroblastoma (Fig. 3A). New associations included
the association of germline TP53, PMS2, and RET
mutations with Ewing’s sarcoma; APC and SDHB
mutations with neuroblastoma; and a variety of
mutations (APC, VHL, CDH1, PTCH1, or SDHA)
with leukemia.
A total of eight children had germline mutations in the adult-onset cancer–predisposition
genes BRCA1, BRCA2, and PALB2. The spectrum
of cancers observed in these children included
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leukemia, CNS tumors, neuroblastoma, osteosarcoma, and rhabdomyosarcoma. Although biallelic mutations of BRCA1/2 and PALB2 are known
to cause Fanconi’s anemia,16-19 there were no
germline mutations or deletions involving the
second alleles of these genes in any of the affected patients.
Medical and Family History

Medical records were available for review for 75
of the 95 patients with mutations that were
deemed to be pathogenic or probably pathogenic. The records showed that only 12 patients
had undergone clinical genetic testing previously. Clinical testing did not identify the predisposing genetic lesions in 2 patients. Of these
2 patients, 1 had an adrenocortical tumor tested
for TP53 (TP53 p.I332F in Patient ACT001) and
1 had retinoblastoma that was tested for RB1
(mosaic RB1 p.R445* in Patient RB002); both
lesions were identified by means of the nextgeneration sequencing approaches used in this
study.
A total of 58 of the 75 records (77%) contained information regarding family history, and
only 23 of 58 records (40%) indicated a family
history of cancer (defined here as one or more
first- or second-degree relatives with cancer)
(Fig. S7 in Supplementary Appendix 1). Furthermore, among these 23 patients, only 13 (57%)
had a history that was consistent with the underlying genetic syndrome, including 8 patients
with TP53 mutations (and thus the Li–Fraumeni
syndrome), 2 with APC mutations (familial adenomatous polyposis), 2 with BRCA2 mutations
(hereditary breast and ovarian cancer; the pedigrees are shown in Fig. S8 in Supplementary
Appendix 1), and 1 with PMS2 mutations (hereditary nonpolyposis colorectal cancer, also known
as the Lynch syndrome). The 8 patients with the
Li–Fraumeni syndrome all met the revised
Chompret criteria regarding family history.20
We completed a similar analysis of a comparison cohort of 100 randomly selected patients
who did not have germline mutations in the
60 autosomal dominant cancer-predisposition
genes. We observed that the percentage of patients with a family history of cancer (42%; 18 of
43 records with family-history information) was
similar to that observed among persons with
germline mutations (40%; 23 of 58 records).
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We identified 4348 nonsilent coding mutations
in the remaining 476 genes that were analyzed.
These included 114 heterozygous truncation mutations, in 109 patients, that involved tumorsuppressor genes, tyrosine kinase genes, or other
cancer genes (Fig. 3D, and Table S5 in Supplementary Appendix 1 and Table S4 in Supplementary Appendix 2). The most commonly affected
tumor-suppressor genes included CHEK2 (in 4 patients), PML (in 4), and BUB1B (in 3). A total of
18 patients who did not have pathogenic mutations in genes that have been associated with
cancer-predisposition syndromes had proteintruncating mutations in tumor-suppressor genes.
Two known hotspots of somatic activating mutations in EGFR, T790 and H773, were identified
once each in the germline of 2 patients with
leukemia (Fig. S6 in Supplementary Appendix 1).

Discussion
In this study involving 1120 children and adolescents with cancer, we found that 8.5% of the
patients had predisposing gene mutations. Sequence coverage exceeded 10× for more than
95% of the coding exons and 20× for more than
85% of the coding exons in the genes of interest
(Table S3 in Supplementary Appendix 1), which
was sufficient for genotype accuracy.21 However,
the prevalence may be underestimated. First, we
included mutations that were pathogenic or
probably pathogenic in 60 genes that have been
associated with clinically relevant autosomal
dominant cancer-predisposition syndromes, and
we did not include other genes that, when mutated, may contribute toward a patient’s susceptibility to cancer. In this regard, we observed
that an additional 38 patients (3.4%) had heterozygous mutations that were pathogenic or probably pathogenic in 29 genes that are known to
be associated with autosomal recessive cancerpredisposition syndromes (Table S4 in Supplementary Appendix 2). Moreover, 109 children
(9.7%) had germline-truncating mutations in
other cancer-associated genes, although nonhotspot missense mutations in these genes were
not fully characterized, some of which may eventually be considered to be cancer-susceptibility
genes.
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Second, among the 226 variants of uncertain
significance that were identified in the 60 genes
that have been associated with autosomal dominant cancer-predisposition syndromes, 119 (52.7%)
were predicted to be deleterious by at least two
computational methods, and some of these
could, in fact, confer susceptibility to cancer.
Third, as sequencing depth increases, additional
mosaic germline mutations will be discovered.
Finally, as we learn more about how certain
genetic alterations (e.g., structural variations,
changes in noncoding regions, and epigenetic
modifications) influence cellular function, new
cancer-predisposing lesions in these and other
newly discovered cancer-associated genes will be
identified.
We found several unexpected germline mutations in patients with Ewing’s sarcoma, neuroblastoma, osteosarcoma, or leukemia. Although
Ewing’s sarcoma has been recognized as a second cancer in children who have been treated for
retinoblastoma,22-25 it has not, to our knowledge,
been associated with other cancer-predisposition
syndromes.26 We found that six patients with
Ewing’s sarcoma had pathogenic germline mutations in TP53 (in four patients), PMS2 (in one),
or RET (in one), although we cannot state with
certainty that each mutation had a bearing on
the patient’s cancer. Additional studies are needed to determine the role, if any, that these germline mutations played in the development of
Ewing’s sarcoma or these other tumors.
Eight patients had heterozygous mutations in
BRCA1, BRCA2, or PALB2. These genes are not
normally examined in children because they are
thought to be predisposition genes for adult cancer. Magnusson et al. described a high prevalence
of childhood cancer in families with germline
BRCA2 mutations,27 and Brooks et al. reported 20
cases of pediatric cancer among 379 families,
members of which had a mutation in either
BRCA1 or BRCA2.28 These reports suggest that
pathogenic mutations in BRCA1 and BRCA2 are
more common in pediatric cancer than has been
recognized previously and that they potentially
underpin a broader spectrum of cancer phenotypes.28-38
Family history is commonly used to identify
persons with a possible heritable predisposition,
especially within the pediatric cancer population.39 However, only 40% of our patients with

germline mutations that were pathogenic or
probably pathogenic and that could be evaluated
had a family history of cancer. In addition, only
half of those had a family history that was consistent with a known cancer-predisposition syndrome. This low frequency probably resulted
from multiple factors, including incomplete information on family history, de novo mutations,
and incomplete penetrance. Furthermore, parents
and other first- or second-degree relatives of our
pediatric patients are often young, and cancer
may not have developed yet. A review of 100
randomly selected patients who did not have
germline cancer-predisposition gene mutations
revealed that 42% had a family history of cancer.
Conceivably, some of these patients have mutations in genes that were not analyzed in the
current study. Nonetheless, on the basis of these
observations, family history cannot be the sole
indication used to guide the provision of genetic
testing.
This study has several limitations. First, several
subtypes of pediatric cancers were not examined. In addition, our cohort included greaterthan-expected proportions of patients with hypodiploid acute lymphoblastic leukemia and those
with adrenocortical tumors. However, after excluding these two subtypes, the prevalence of
germline mutations of 5.6% was still significantly higher than the prevalence in two control
cohorts (P<10−7 by Fisher’s exact test for both
comparisons). Observation of pathogenic mutations in the controls may indicate uncharacterized cancer phenotypes in the people enrolled,
rather than refuting the pathogenicity of these
mutations in cancer predisposition (Tables S6
and S7 in Supplementary Appendix 1). Moreover,
by adjusting for the distribution of cancer subtypes observed in the SEER program and by applying previously reported mutation frequencies
for those not included in this study, we predicted
an overall mutation prevalence of 7.3 to 9.8% in
the SEER pediatric cancer population (Table S10
in Supplementary Appendix 2).
Second, we did not study the parents or relatives of the patients in our cohort and hence
could not assess whether variants were new or
segregated with a cancer phenotype among family members. This information could have augmented the evidence of pathogenicity in some
cases. Nonetheless, the discovery of four mosaic
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germline mutations in TP53 and RB1 indicates
that a fraction of the mutations that were identified in this study were de novo. Third, although
the 60 autosomal dominant cancer-predisposition genes that were the focus of this report have
been well characterized, information regarding
the penetrance of many mutations that were
identified within these genes is lacking. Additional family, epidemiologic, and functional studies are warranted to better understand the cancer risks associated with each of these variants.
In conclusion, germline mutations in cancerpredisposing genes were identified in 8.5% of
the children and adolescents with cancer who
participated in this study. Family history did not
predict the presence of an underlying predisposition syndrome in most patients. The germline
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